Dimitry Sa Nuyten Net Worth

The estimated Net Worth of Dimitry Sa Nuyten is at least $153 ezer dollars as of 7 August 2020. Dimitry Nuyten owns over 3,538 units of Arcus Biosciences Inc stock worth over $143,600 and over the last 6 years Dimitry sold RCUS stock worth over $9,022.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Dimitry Nuyten RCUS stock SEC Form 4 insiders trading

Dimitry has made over 1 trades of the Arcus Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Dimitry sold 3,538 units of RCUS stock worth $9,022 on 7 August 2020.

The largest trade Dimitry's ever made was selling 3,538 units of Arcus Biosciences Inc stock on 7 August 2020 worth over $9,022. On average, Dimitry trades about 393 units every 0 days since 2019. As of 7 August 2020 Dimitry still owns at least 8,462 units of Arcus Biosciences Inc stock.

You can see the complete history of Dimitry Nuyten stock trades at the bottom of the page.

What's Dimitry Nuyten's mailing address?

Dimitry's mailing address filed with the SEC is C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD, CA, 94545.

Insiders trading at Arcus Biosciences Inc

Over the last 7 years, insiders at Arcus Biosciences Inc have traded over $12,714,957 worth of Arcus Biosciences Inc stock and bought 22,383,260 units worth $566,530,309 . The most active insiders traders include Patrick Machado, Sciences, Inc. Gilead és Harbor Master Investors (Ca.... On average, Arcus Biosciences Inc executives and independent directors trade stock every 32 days with the average trade being worth of $5,400,635. The most recent stock trade was executed by Alexander Azoy on 13 August 2024, trading 1,357 units of RCUS stock currently worth $20,314.

What does Arcus Biosciences Inc do?

arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be

Complete history of Dimitry Nuyten stock trades at Aduro BioTech és Arcus Biosciences Inc

Arcus Biosciences Inc executives and stock owners

Arcus Biosciences Inc executives and other stock owners filed with the SEC include:

• William Grossman,
  Chief Medical Officer
• Juan Jaen,
  President, Co-Founder, Director
• Terry Rosen,
  Chairman of the Board, Chief Executive Officer, Co-Founder
• Jennifer Jarrett M.B.A.,
  COO & Director
• Jennifer Jarrett,
  Chief Operating Officer, Director
• Patrick Machado,
  Director
• Antoni Ribas,
  Director
• Yasunori Kaneko,
  Lead Independent Director
• Kathryn Falberg,
  Independent Director
• Merdad Parsey,
  Director
• David Lacey,
  Director
• Eric Hoefer,
  Chief Commercial Officer & Head of Business Development
• Jason Barker,
  Vice President - Finance
• Robert Goeltz,
  Chief Financial Officer, Principal Financial and Accounting Officer
• Yvonne Gehring,
  VP of HR & Operations
• Holli Kolkey,
  VP of Corp. Communications
• Carolyn C. Tang J.D.,
  Gen. Counsel & Corp. Sec.
• Katherine Bock,
  VP of Investor Relations & Corp. Strategy
• Dr. Jonathan Yingling Ph.D.,
  Chief Scientific Officer
• Dr. Stephen Young Ph.D.,
  Sr. VP of Technology & Quantitative Biology
• Robert C. Goeltz II,
  Principal Financial & Accounting Officer and CFO
• Dr. Juan Carlos Jaen Ph.D.,
  Co-Founder, Pres & Director
• David W Beier,
  Director
• Carolyn C. Tang,
  General Counsel
• Harbor Master Investors (Ca...,
  10% owner
• 2016 Gp, L.L.C.Gv 2016 Gp, ...,
  
• 2017 Gp, L.L.C.Gv 2017 Gp, ...,
  
• Group Ii, Lp Column Group I...,
  
• Kristen Hege,
  Director
• Steven Chan,
  See Remarks
• Rekha Hemrajani,
  See Remarks
• Sciences, Inc. Gilead,
  10% owner
• Nicole Lambert,
  Director
• Dimitry Sa Nuyten,
  Chief Medical Officer
• Alexander Azoy,
  Chief Accounting Officer